Erlotinib-associated near-fatal interstitial pneumonitis in A patient with relapsed lung adenocarcinoma

Chun Liang Chou, How Wen Ko, Chih Wei Wang, Chih Teng Yu, Han Pin Kuo, Chien Da Huang

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Erlotinib (Tarceva®) is a human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. Interstitial lung disease, associated with gefitinib (Iressa®) use, has been reported in approximately 1% of patients worldwide. However, the adverse pulmonary effects of erlotinib remain poorly documented. Reviewed English language publications in MEDLINE and PubMed suggest that this report is to be the first case report in English of a histologically-confirmed case of nearfatal interstitial pneumonitis with acute lung injury, associated with erlotinib, in East Asian patients. Physicians are hereby encouraged to promptly evaluate new or worsening pulmonary symptoms so that they can detect early radiographic signs of pulmonary toxicity in patients on erlotinib. If toxicity is confirmed, erlotinib should be discontinued and the patient treated appropriately. The case presented suggests that the outcome of erlotinib-associated pulmonary toxicity with acute respiratory failure may be favorable with adequate early management.

Original languageEnglish
Pages (from-to)100-105
Number of pages6
JournalChang Gung Medical Journal
Issue number1
Publication statusPublished - Jan 1 2010
Externally publishedYes


  • East Asia
  • EGFR
  • Erlotinib
  • Interstitial pneumonitis
  • Lung cancer

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Erlotinib-associated near-fatal interstitial pneumonitis in A patient with relapsed lung adenocarcinoma'. Together they form a unique fingerprint.

Cite this